Adam Sperling

34PUBLICATIONS
279CO-AUTHORS
Regenerative medicine (incl. stem cells)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Sep 12, 2026
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.

|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

|Apr 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

|Dec 11, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

Anil Aktas Samur, Jill Corre, Srikanth Talluri

|Nov 18, 2025
Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.

Maroulio Pertesi, Delphine Demangel, Abhishek Niroula

|Oct 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Clifton C Mo, Yuxin Liu, Omar Nadeem

Pageof 6

Frequent Collaborators

10 joint publications

Nikhil Munshi

7 joint publications

Kenneth C Anderson

7 joint publications

Shonali Midha

7 joint publications

Omar Nadeem